Nafarelin (original) (raw)

dbo:abstract

نافاريلين (بالإنجليزية: Nafarelin)‏ هو دواء يُستعمل في علاج: * انتباذ بطاني رحمي (ar)
Nafarelin, sold under the brand name Synarel among others, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in the treatment of endometriosis and early puberty. It is also used to treat uterine fibroids, to control ovarian stimulation in in vitro fertilization (IVF), and as part of transgender hormone therapy. The medication is used as a nasal spray two to three times per day. Side effects of nafarelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis. Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. It can lower sex hormone levels by 95% in both sexes. Nafarelin is a peptide and an analogue of GnRH. Nafarelin was introduced for medical use in 1990. It is available widely throughout the world, including in North America, Europe, and elsewhere throughout the world. The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being buserelin. (en)
Il nafarelin (conosciuto anche con il nome di nafarelina e D-Nal(2)6-LHRH) è un decapeptide di sintesi, analogo dei fattori di rilascio delle gonadotropine naturali (GnRH) e presenta proprietà simili alla . La sostituzione della glicina in posizione 6 della gonadorelina con una D-naftilalanina aumenta l'idrofobia e rallenta la degradazione enzimatica della nafarelina. La nafarelina viene somministrata in dose singola, come spray nasale, e stimola la secrezione delle gonadotropine ipofisarie, LH e FSH, e di conseguenza stimola la secrezione degli ormoni steroidei delle ovaie e dei testicoli. (it)
Nafarrelina é um fármaco agonista do hormônio liberador de gonadotrofina (LHRH). Tem utilização na endometriose, fertilização em vitro, puberdade precoce e em terapia hormonal feminizante. (pt)

dbo:alternativeName

Synarel, others (en)

dbo:casNumber

76932-56-4
76932-60-0 (acetate)

dbo:chEBI

7445

dbo:chEMBL

1201309

dbo:class

dbo:drugbank

DB00666

dbo:fdaUniiCode

1X0094V6JV

dbo:kegg

D08241

dbo:medlinePlus

a601082

dbo:pubchem

25077649

dbo:thumbnail

wiki-commons:Special:FilePath/Nafarelin.svg?width=300

dbo:wikiPageID

2102271 (xsd:integer)

dbo:wikiPageLength

21255 (xsd:nonNegativeInteger)

dbo:wikiPageRevisionID

1095366784 (xsd:integer)

dbo:wikiPageWikiLink

dbp:atcPrefix

H01 (en)

dbp:atcSuffix

CA02 (en)

dbp:bioavailability

: 2.8% (en)

dbp:c

66 (xsd:integer)

dbp:casNumber

76932 (xsd:integer)

dbp:casSupplemental

76932 (xsd:integer)

dbp:chebi

7445 (xsd:integer)

dbp:chembl

1201309 (xsd:integer)

dbp:chemspiderid

10482014 (xsd:integer)

dbp:class

dbp:drugbank

DB00666 (en)

dbp:eliminationHalfLife

-10800.0

dbp:excretion

Feces: 19–44% (en)
Urine: 44–55% (en)

dbp:h

83 (xsd:integer)

dbp:iupacName

-N-[-5-carbamimidamido-1-[-2-[carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[-2-[-2-[-3-hydroxy-2-[-2-[-3--2-{[-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-propanamido]propanamido]-3-propanamido]-3-propanamido]-4-methylpentanamide (en)

dbp:iupharLigand

3902 (xsd:integer)

dbp:kegg

D08241 (en)

dbp:legalStatus

Rx-only (en)

dbp:medlineplus

a601082 (en)

dbp:metabolism

Peptidases (en)

dbp:n

17 (xsd:integer)

dbp:o

13 (xsd:integer)

dbp:pregnancyCategory

X (en)

dbp:proteinBound

80.0

dbp:pubchem

25077649 (xsd:integer)

dbp:routesOfAdministration

dbr:Nasal_spray

dbp:smiles

CCC[C@H]CN[C@@H]CN1CCC[C@H]1CNCC=O (en)

dbp:stdinchi

1 (xsd:integer)

dbp:stdinchikey

RWHUEXWOYVBUCI-ITQXDASVSA-N (en)

dbp:synonyms

Nafareline; Nafarelin acetate; RS-94991; RS-94991-298; [6-(D)-alanine]-GnRH (en)

dbp:tradename

Synarel, others (en)

dbp:unii

1 (xsd:integer)

dbp:verifiedfields

verified (en)

dbp:verifiedrevid

462258124 (xsd:integer)

dbp:watchedfields

verified (en)

dbp:width

250 (xsd:integer)

dbp:wikiPageUsesTemplate

dcterms:subject

gold:hypernym

dbr:Agonist

rdf:type

rdfs:comment

نافاريلين (بالإنجليزية: Nafarelin)‏ هو دواء يُستعمل في علاج: * انتباذ بطاني رحمي (ar)
Il nafarelin (conosciuto anche con il nome di nafarelina e D-Nal(2)6-LHRH) è un decapeptide di sintesi, analogo dei fattori di rilascio delle gonadotropine naturali (GnRH) e presenta proprietà simili alla . La sostituzione della glicina in posizione 6 della gonadorelina con una D-naftilalanina aumenta l'idrofobia e rallenta la degradazione enzimatica della nafarelina. La nafarelina viene somministrata in dose singola, come spray nasale, e stimola la secrezione delle gonadotropine ipofisarie, LH e FSH, e di conseguenza stimola la secrezione degli ormoni steroidei delle ovaie e dei testicoli. (it)
Nafarrelina é um fármaco agonista do hormônio liberador de gonadotrofina (LHRH). Tem utilização na endometriose, fertilização em vitro, puberdade precoce e em terapia hormonal feminizante. (pt)
Nafarelin, sold under the brand name Synarel among others, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in the treatment of endometriosis and early puberty. It is also used to treat uterine fibroids, to control ovarian stimulation in in vitro fertilization (IVF), and as part of transgender hormone therapy. The medication is used as a nasal spray two to three times per day. (en)

rdfs:label

نافاريلين (ar)
Nafarelin (it)
Nafarelin (en)
Nafarrelina (pt)

owl:sameAs

prov:wasDerivedFrom

wikipedia-en:Nafarelin?oldid=1095366784&ns=0

foaf:depiction

wiki-commons:Special:FilePath/Nafarelin.svg

foaf:isPrimaryTopicOf

wikipedia-en:Nafarelin

is dbo:wikiPageRedirects of

is dbo:wikiPageWikiLink of

is foaf:primaryTopic of

wikipedia-en:Nafarelin